Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.

DRUG

Oxaliplatin

"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"

Trial Locations (7)

29303

Spartanburg Regional Medical Center, Spartanburg

37205

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology and Hematology Associates, Chattanooga

42101

Graves-Gilbert Clinic, Bowling Green

45242

Oncology Hematology Care, Cincinnati

70806

Baton Rouge General Medical Center, Baton Rouge

71301

Hematology Oncology Life Center, Alexandria

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00297596 - Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter